scispace - formally typeset
M

Mark M. Souweidane

Researcher at Cornell University

Publications -  275
Citations -  7762

Mark M. Souweidane is an academic researcher from Cornell University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 44, co-authored 232 publications receiving 6520 citations. Previous affiliations of Mark M. Souweidane include University of Toronto & Memorial Sloan Kettering Cancer Center.

Papers
More filters
Journal ArticleDOI

Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations

TL;DR: This work integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPG.
Journal ArticleDOI

Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.

TL;DR: Assessment of the primary outcome variable suggests a slowing of progression of LINCL in the treated children, and it is proposed that additional studies to assess the safety and efficacy of AAV-mediated gene therapy for LINCL are warranted.
Journal ArticleDOI

An integrated functional magnetic resonance imaging procedure for preoperative mapping of cortical areas associated with tactile, motor, language, and visual functions.

TL;DR: This integrated fMRI task battery offers standardized and noninvasive preoperative maps of multiple critical functions to facilitate assessment of surgical risk, planning of surgical routes, and direction of conventional, intraoperative electrophysiological procedures.
Journal ArticleDOI

Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma.

TL;DR: The cRIT-salvage regimen for CNS metastases was well tolerated by young patients, despite their prior history of intensive cytotoxic therapies, and has the potential to increase survival with better than expected quality of life.